GSK and SK bioscience's COVID vaccine submitted for S.Korea approval

SK Bioscience Co

29/04/2022 08:23

April 29 (Reuters) - GlaxoSmithKline's (GSK)  GSK.L 
COVID-19 vaccine candidate developed with SK bioscience
 302440.KS  has been submitted for regulatory approval in South
Korea after positive positive Phase III clinical data, the
British drugmaker said on Friday.
    GSK said that SK bioscience will also apply to the World
Health Organization (WHO) for emergency use listing and seek
authorisations at individual regulatory agencies around the
world. 
    The company said an extended clinical trial is planned to 
test the vaccine's effectiveness against the Omicron variant of
the virus.  

 (Reporting by Miyoung Kim
Editing by David Goodman
)
 ((miyoung.kim@thomsonreuters.com; 65 6870 3026; Reuters
Messaging: miyoung.kim.thomsonreuters.com@reuters.net))